Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesThe feasibility and safety of high-intensity focused ultrasound combined with low-dose external beam radiotherapy as supplemental therapy for advanced prostate cancer following hormonal therapy.High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-upAn update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsCritical review of prostate cancer predictive toolsAndrogen deprivation therapy for prostate cancer-review of indications in 2010Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trialThe 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancerRole of pelvic lymph node dissection in prostate cancer treatmentHelical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratificatThe outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer.Comprehensive microRNA Profiling of Prostate CancerIntegration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialRadiotherapy and Hormone Treatment in Prostate CancerRole of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer.Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.Predictive value of positive surgical margins after radical prostatectomy for lymph node metastasis in locally advanced prostate carcinomaHypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity.Obstructive urination problems after high-dose-rate brachytherapy boost treatment for prostate cancer are avoidable.Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion.Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol.Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT.Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes.Whole-pelvic volumetric-modulated arc therapy for high-risk prostate cancer: treatment planning and acute toxicity.Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancerDoes intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.Definitive Radiotherapy for Older Patients with Prostate Cancer: Experience of a Medical Center in TaiwanTreatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon.Predictive Factors of Late-onset Rectal Mucosal Changes After Radiotherapy of Prostate Cancer.Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
P2860
Q26744606-58965012-46FB-4183-B9F6-9CB6833E5F2DQ30449403-2C9430F6-04D2-466C-A155-66DA44E59FDDQ33582598-12464846-B1C3-4D10-82D5-CE2E389AD871Q34048630-26B83873-8748-4F5F-8202-58EB0F209076Q34104562-803CFA5E-5EBE-4AC1-8723-63E1D4F2F097Q34111603-4B7B0B84-DE35-465B-ABE1-3B9C8DF04A97Q34187079-C64DA962-927D-4332-9890-94B84C9A707AQ34462816-4AF82661-E350-435D-B77F-73F01719AC48Q34960819-AEF6751B-A331-4A3A-8F49-399988BB4466Q35111775-D17AEAEF-495C-4D20-A771-FF2330192D48Q35151980-12854C49-F354-47BD-B265-FC78759A8563Q35835108-BDE9B397-7067-4F00-8018-250AFB541CC9Q36133745-E5FDD197-18BC-4211-8578-32B2A7E7785DQ36259082-C98752F4-7E4D-46EE-8E37-CADD14CF7747Q36315170-6F5AD808-E4D1-490F-A0D8-9D43C7166747Q36474222-0CCFDA69-E9F9-4508-8CBF-528F0376EF52Q36684017-CE125FF0-4970-4DBA-AF3B-97C35BE581BFQ36916050-7414B6C2-BC47-4372-8889-4F3DDAC6CC7BQ36942136-37FE676C-8EE7-4805-96A8-906DB679B414Q37128114-1B817A96-35CF-4D55-A282-0E7A9CD0A541Q37176612-0E445F02-5090-4A70-B360-7178D1136E5BQ37283766-D2CDC86B-3473-4801-B4D1-5EA487215DB8Q37396108-0F557650-5192-4702-AFBE-93D090D7D622Q37485229-AA52A1B8-0EBD-4781-901A-4B4264406885Q38610879-AFF4D85F-44AB-4090-87E8-24580E030192Q38746814-3B73B646-E1FF-40A2-9D07-D4639E3674B4Q39978570-36C35E5B-58CF-461F-BD0A-AB6D1F616784Q41533266-9076DD3F-827F-4930-8130-4F51E3DCA4D3Q41543779-7A9B67F2-353D-4E7B-9A23-78BB69A9C345Q41830239-AFFDDA3E-1B4D-470A-9A75-423A876F99BAQ41886788-7F8EE032-B932-4E7D-A262-D4C54D4C6C17Q41897302-82194586-DFB3-4EEA-AFF5-DF95B9A01D8AQ41985869-254047CA-DE5D-4090-927A-25348C99B28CQ41994836-EE52A23A-46A0-4EFC-BC5C-7734EE399319Q42032625-FB801D61-81FA-4292-9461-8B2E17A9DDDAQ42537805-CFA5D250-A5DD-4B8F-976B-B6F17525E671Q42635303-8ED9B6E2-3BC3-44D2-BD1D-459B5B7E1322Q42941156-0C615353-32C2-4F04-976A-17BEE906F43AQ43246964-C2CDF0AE-8BEB-4D67-BD98-55B7934F3BBAQ45198533-8A29763F-6989-43D5-9C35-10A7F1CBF997
P2860
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Predicting the risk of lymph n ...... lly localized prostate cancer.
@en
type
label
Predicting the risk of lymph n ...... lly localized prostate cancer.
@en
prefLabel
Predicting the risk of lymph n ...... lly localized prostate cancer.
@en
P2093
P1476
Predicting the risk of lymph n ...... ally localized prostate cancer
@en
P2093
P R Carroll
P356
10.1016/0360-3016(94)90138-4
P407
P577
1994-01-01T00:00:00Z